ArgenX highlights new Vyvgart data, demonstrating early disease control in ocular MG
On 26 February, ArgenX announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the Phase III Adapt…
Analyst Comment
DOR/ISL Phase III data underlines trend for shift towards two-drug STRs in HIV
FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market
Greater intake of caffeinated coffee and tea lowers dementia
A dose of optimism: WHO prequalifies new oral polio vaccine
Obesity associated with increased infectious disease risk
Brazilian study shows increase in Covid-19-era substance abuse-related deaths
WHO analysis shows four in ten cancers could be prevented
